Qure.ai Receives FDA Clearance for qXR-CTR AI Solution to Assess Cardiomegaly

This technology harnesses artificial intelligence algorithms, significantly enhancing efficiency and accuracy, aiding physicians, and advancing diagnostic precision.

Qure.ai, a Mumbai-based medical imaging AI company, has received FDA clearance for qXR-CTR, its artificial intelligence-enabled chest X-ray solution.

The qXR-CTR employs a deep-learning-based computer vision algorithm, purposefully crafted for physicians across inpatient and outpatient settings, to automate the assessment of cardiothoracic ratio (CTR) on chest radiographs (CXR).

It accurately measures the heart's maximum transverse diameter ratio to the thoracic cavity's maximum inner transverse diameter, indicating cardiomegaly on plain film. 

This technology harnesses artificial intelligence algorithms, significantly enhancing efficiency and accuracy, aiding physicians, and advancing diagnostic precision.

Prashant Warier, cofounder and CEO at Qure.ai, said, "This state-of-the-art algorithm elevates the precision and efficiency of CTR assessment, equipping healthcare professionals with a valuable tool to diagnose and monitor the risk of heart failure."

Heart failure, a complex and potentially life-threatening cardiac condition, often presents nonspecific symptoms, leading to misdiagnosis. With qXR-CTR now FDA-cleared, Qure's chest X-ray algorithm can be employed to jointly screen for an increased cardiothoracic ratio (CTR) and Pleural effusion, along with other radiographic markers associated with the presence of heart failure. 

Dr. Tariq Ahmad, chief of the Heart Failure Program at Yale School of Medicine, said, "Early detection of heart failure is a challenge, but we are narrowing the gap with tools like these. I believe this amplifies AI-driven solutions' crucial role in supporting cardiologists and enhancing patient outcomes."

Established in 2016 by CEO Prashant Warier, Qure.ai is a global player in medical AI. Headquartered in India, with offices in London and New York, the company operates in over 70 countries. 

Their certified medical imaging AI solutions cover a range of medical applications, from analysing neurocritical trauma or stroke CTs to detecting musculoskeletal X-ray fractures and identifying lung cancer, tuberculosis, and heart failure through chest X-rays and CT scans. 

Previous Qure.ai FDA-cleared findings include crucial aspects such as Endotracheal Tube location, Tracheostomy tube location, tracheostomy tube location, Pneumothorax, Pleural Effusion identification for CXR, as well as qER for intracranial hemorrhage detection on head CT scans and qER Quant for quantifying critical abnormalities on head CT scans.